204 related articles for article (PubMed ID: 17638735)
1. Efalizumab-associated papular psoriasis.
Hassan AS; Simon D; Simon HU; Braathen LR; Yawalkar N
Arch Dermatol; 2007 Jul; 143(7):900-6. PubMed ID: 17638735
[TBL] [Abstract][Full Text] [Related]
2. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
[TBL] [Abstract][Full Text] [Related]
3. Exacerbation of psoriasis under efalizumab therapy.
Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
[TBL] [Abstract][Full Text] [Related]
4. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
[TBL] [Abstract][Full Text] [Related]
5. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
7. Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH; Langley RG; Ho V
J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
[TBL] [Abstract][Full Text] [Related]
8. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab-associated papular psoriasis: an adverse reaction to efalizumab in three cases.
Antonucci A; Bardazzi F; Balestri R; Patrizi A
J Dermatolog Treat; 2009; 20(1):61-2. PubMed ID: 18618361
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
[TBL] [Abstract][Full Text] [Related]
12. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
[TBL] [Abstract][Full Text] [Related]
13. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
15. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
Lowes MA; Turton JA; Krueger JG; Barnetson RS
BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
[TBL] [Abstract][Full Text] [Related]
17. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
18. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Gordon KB; Lebwohl MG; Caro I; Walicke PA; Li N; Leonardi CL;
J Drugs Dermatol; 2004; 3(6):614-24. PubMed ID: 15624744
[TBL] [Abstract][Full Text] [Related]
19. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of hand and foot psoriasis with efalizumab therapy.
Fretzin S; Crowley J; Jones L; Young M; Sobell J
J Drugs Dermatol; 2006 Oct; 5(9):838-46. PubMed ID: 17039648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
